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1. INTRODUCTION {#cas13526-sec-0001}
===============

Renal cell carcinoma (RCC) is the most common form of kidney cancer and is diagnosed in more than 350 000 patients worldwide, making it the seventh most common site for tumors.[1](#cas13526-bib-0001){ref-type="ref"} Although patients with stage I RCC had a 5‐years survival rate above 90%, those with advanced RCC had a 5‐years survival rate of only 23%.[2](#cas13526-bib-0002){ref-type="ref"} In fact, 25%‐30% of patients have metastasis at the time of diagnosis.[3](#cas13526-bib-0003){ref-type="ref"} Furthermore, distant metastasis and recurrence are found even when surgical resection is carried out for localized RCC, cases that are associated with poor prognosis. Recently, molecular targeted therapy and immunotherapy have been used for patients with metastatic or recurrent RCC. However, the therapeutic benefits are limited, and RCC is generally insensitive to radiation and chemotherapy. Thus, development of novel therapeutic strategies is needed.[2](#cas13526-bib-0002){ref-type="ref"} We believe that novel genomic approaches are required to elucidate the underlying molecular mechanism of metastatic RCC.

MicroRNA (miRNA) is a single‐stranded low molecular RNA of 19‐22 bases that possesses important functions. For example, miRNA regulates the expression of target genes by inhibiting translation and/or accelerates the degradation of functional RNAs (protein coding/non‐protein coding genes).[4](#cas13526-bib-0004){ref-type="ref"}, [5](#cas13526-bib-0005){ref-type="ref"} In human cells, a single miRNA can regulate many different protein‐coding or non‐coding mRNAs and a single mRNA can be regulated by several different miRNAs.[6](#cas13526-bib-0006){ref-type="ref"} Thus, aberrant expression of miRNA could disrupt regulated RNA networks in cancer cells. Therefore, it is important to elucidate the aberrant expression of miRNAs in each type of cancer to better understand the molecular mechanism of cancer pathogenesis.[4](#cas13526-bib-0004){ref-type="ref"}, [7](#cas13526-bib-0007){ref-type="ref"}, [8](#cas13526-bib-0008){ref-type="ref"}

We previously identified antitumor miRNAs that regulated novel oncogenic pathways based on miRNA expression signatures.[9](#cas13526-bib-0009){ref-type="ref"}, [10](#cas13526-bib-0010){ref-type="ref"}, [11](#cas13526-bib-0011){ref-type="ref"}, [12](#cas13526-bib-0012){ref-type="ref"} Downregulation of *miR‐451a* was detected by our studies of miRNA signatures and several types of cancers.[12](#cas13526-bib-0012){ref-type="ref"}, [13](#cas13526-bib-0013){ref-type="ref"}, [14](#cas13526-bib-0014){ref-type="ref"}, [15](#cas13526-bib-0015){ref-type="ref"}, [16](#cas13526-bib-0016){ref-type="ref"}, [17](#cas13526-bib-0017){ref-type="ref"}, [18](#cas13526-bib-0018){ref-type="ref"} Moreover, a large cohort analysis using The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>) showed that low expression of *miR‐451a* was associated with poor survival of patients with RCC. The antitumor role of *miR‐451a* in RCC has been reported;[19](#cas13526-bib-0019){ref-type="ref"} however, the molecular pathways regulated by *miR‐451a* have not been fully elucidated. MicroRNA biogenesis is unique, in that a single miRNA can target a vast number of RNAs in cells. Continuous analyses of antitumor miRNA‐regulated molecular pathways are essential for understanding RCC pathogenesis. Here, we aimed to investigate novel oncogenic pathways regulated by antitumor *miR‐451a* in RCC cells and involving in RCC pathogenesis.

2. MATERIALS AND METHODS {#cas13526-sec-0002}
========================

2.1. Patients, cancer tissue collection, cell lines, and cell culture {#cas13526-sec-0003}
---------------------------------------------------------------------

We postoperatively collected cancerous and normal tissues from 15 RCC patients at Chiba University Hospital (Chiba, Japan) between 2012 and 2015. Clinicopathological characteristics of the 15 patients are listed in Table [1](#cas13526-tbl-0001){ref-type="table-wrap"}. Tumor stages were determined by the General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma based on the AJCC‐UICC TNM classification. All patients gave signed, informed consent for the use of the tissues for research purposes.

###### 

Clinical features of 15 patients with clear cell renal cell carcinoma

  Patient no.   Age, years   Gender   Grade            pT    INF   v   ly   eg or ig   fc   im   rc   rp   s
  ------------- ------------ -------- ---------------- ----- ----- --- ---- ---------- ---- ---- ---- ---- ---
  1             71           F        G2               T1a   a     0   0    eg         1    0    0    0    0
  2             74           M        G1 \> G2         T1a   a     0   0    eg         1    0    0    0    0
  3             59           M        G3 \> G2         T1b   a     0   0    eg         1    0    0    0    0
  4             52           M        G2 \> G3 \> G1   T1a   a     0   0    eg         1    0    0    0    0
  5             64           M        G2 \> G3         T1b   a     0   0    eg         1    1    0    0    0
  6             67           M        G2 \> G3 \> G1   T3a   b     1   0    ig         0    1    1    0    0
  7             67           M        G2 \> G3 \> G1   T3a   b     1   0    ig         1    0    0    0    0
  8             59           M        G3 \> G2         T3a   b     1   0    ig         0    0    0    0    0
  9             73           M        G1 \> G3         T2a   a     0   1    eg         1    0    0    0    0
  10            77           M        G1 \> G2         T1b   a     0   0    eg         1    0    0    0    0
  11            77           M        G2 \> G1         T3a   a     1   0    eg         1    0    0    0    0
  12            51           M        G2 \> G1         T1    a     0   0    eg         0    0    0    0    0
  13            78           M        G2 \> G1 \> G3   T1b   b     0   0    eg         1    0    0    0    0
  14            57           M        G1 \> G2         T1a   a     0   0    eg         1    0    0    0    0
  15            54           M        G2 \> G1         T3a   a     0   0    eg         0    0    1    0    0

eg, expansive growth; F, female; fc, capsular formation; ig, infiltrative growth; im, intrarenal metastasis; INF, infiltration; ly, lymph node; M, male; rc, renal capsule invasion; rp, pelvis invasion; s, sinus invasion; v, vein.
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We used 2 human RCC cell lines (786‐O and A498) obtained from ATCC (Manassas, VA, USA) as previously described.[20](#cas13526-bib-0020){ref-type="ref"}, [21](#cas13526-bib-0021){ref-type="ref"}, [22](#cas13526-bib-0022){ref-type="ref"}, [23](#cas13526-bib-0023){ref-type="ref"}, [24](#cas13526-bib-0024){ref-type="ref"}, [25](#cas13526-bib-0025){ref-type="ref"} These cell lines were maintained in RPMI‐1640 with 10% FBS (HyClone, Logan, UT, USA).

2.2. Transfections with mature miRNA, siRNA, or plasmid vectors {#cas13526-sec-0004}
---------------------------------------------------------------

We used the following mature miRNA species in these experiments: mature miRNA and pre‐miR miRNA precursors (*has‐miR‐451a*; P/N: AM17100; Applied Biosystems, Foster City, CA, USA). The following siRNAs were used: Stealth Select RNAi siRNA, si‐*PMM2* (HSS108164 and HSS108165; Invitrogen, Carlsbad, CA, USA), and negative control miRNA/siRNA (P/N: AM17111; Applied Biosystems). *PMM2* plasmid vectors were designed and provided by OriGene (cat. no. RC203472; Rockville, MD, USA). MicroRNAs and siRNAs were incubated with Opti‐MEM (Invitrogen) and Lipofectamine RNAiMax transfection reagent (Invitrogen), as previously described.[22](#cas13526-bib-0022){ref-type="ref"}, [26](#cas13526-bib-0026){ref-type="ref"} Plasmid vectors were incubated with Opti‐MEM and Lipofectamine 3000 reagent (Invitrogen) by forward transfection following the manufacturer\'s protocol.

2.3. Quantitative real‐time RT‐PCR {#cas13526-sec-0005}
----------------------------------

Total RNA was extracted from human tissues and cell lines using TRIzol reagent (Invitrogen) according to the manufacturer\'s protocol, as we described previously.[20](#cas13526-bib-0020){ref-type="ref"}, [21](#cas13526-bib-0021){ref-type="ref"}, [22](#cas13526-bib-0022){ref-type="ref"}, [23](#cas13526-bib-0023){ref-type="ref"}, [24](#cas13526-bib-0024){ref-type="ref"}, [25](#cas13526-bib-0025){ref-type="ref"} The procedure for PCR quantification has been outlined. Expression levels of *miR‐451a* (assay ID:001141; Applied Biosystems) were analyzed by TaqMan quantitative real‐time RT‐PCR (qRT‐PCR) (TaqMan MicroRNA Assay; Applied Biosystems) and normalized to the expression of *RNU48* (assay ID: 001006; Applied Biosystems). TaqMan probes and primers for *PMM2* (P/N: Hs00756707_m1; Applied Biosystems), *GAPDH* (internal control; P/N: Hs02758991_m1; Applied Biosystems), and *GUSB* (internal control; P/N: Hs00939627_ml; Applied Biosystems) were assay‐on‐demand gene expression products. The relative expression levels were calculated using the 2^−ΔΔCT^ method.

2.4. Cell proliferation, migration, and invasion assays {#cas13526-sec-0006}
-------------------------------------------------------

Cell proliferation, migration, and invasion assays have been described.[20](#cas13526-bib-0020){ref-type="ref"}, [21](#cas13526-bib-0021){ref-type="ref"}, [22](#cas13526-bib-0022){ref-type="ref"}, [23](#cas13526-bib-0023){ref-type="ref"}, [24](#cas13526-bib-0024){ref-type="ref"}, [25](#cas13526-bib-0025){ref-type="ref"}

2.5. Identification of putative target genes regulated by *miR‐451a* in RCC cells {#cas13526-sec-0007}
---------------------------------------------------------------------------------

To identify *miR‐451a* target genes, we used in silico analyses and genome‐wide gene expression analyses, as outlined previously.[20](#cas13526-bib-0020){ref-type="ref"}, [21](#cas13526-bib-0021){ref-type="ref"}, [22](#cas13526-bib-0022){ref-type="ref"}, [23](#cas13526-bib-0023){ref-type="ref"}, [24](#cas13526-bib-0024){ref-type="ref"}, [25](#cas13526-bib-0025){ref-type="ref"} We used the TargetScanHuman 7.0 (August 2015 release) (<http://www.targetscan.org/>), TCGA, and OncoLnc datasets (<http://www.oncolnc.org/>) to select and narrow down putative miRNA target genes.[27](#cas13526-bib-0027){ref-type="ref"}, [28](#cas13526-bib-0028){ref-type="ref"}, [29](#cas13526-bib-0029){ref-type="ref"} An oligo microarray (Human Ge 60K; Agilent Technologies) was used for gene expression analysis. We deposited the microarray data into the Gene Expression Omnibus (GEO) database.

2.6. Western blot analysis {#cas13526-sec-0008}
--------------------------

Cells were collected 48 hours after transfection, and lysates were prepared. Immunoblotting was undertaken with rabbit anti‐PMM2 antibodies (1:500 dilution, SAB2702078; Sigma‐Aldrich, St. Louis, MO, USA). Anti‐GAPDH antibodies (1:10 000, ab8245; Abcam) were used as an internal loading control. The procedures have been described.[20](#cas13526-bib-0020){ref-type="ref"}, [21](#cas13526-bib-0021){ref-type="ref"}, [22](#cas13526-bib-0022){ref-type="ref"}, [23](#cas13526-bib-0023){ref-type="ref"}, [24](#cas13526-bib-0024){ref-type="ref"}, [25](#cas13526-bib-0025){ref-type="ref"}

2.7. Plasmid construction and dual luciferase reporter assays {#cas13526-sec-0009}
-------------------------------------------------------------

The partial wild‐type sequence of the *PMM2* 3′‐UTR or that with deletion of the *miR‐451a* putative target site was inserted between the *Sgf*I‐*Pme*I restriction sites in the 3′‐UTR of the *hRluc* gene in the psiCHECK‐2 vector (C8021; Promega, Madison, WI, USA). The procedures were covered in earlier reports.[20](#cas13526-bib-0020){ref-type="ref"}, [21](#cas13526-bib-0021){ref-type="ref"}, [22](#cas13526-bib-0022){ref-type="ref"}, [23](#cas13526-bib-0023){ref-type="ref"}, [24](#cas13526-bib-0024){ref-type="ref"}, [25](#cas13526-bib-0025){ref-type="ref"}

2.8. Immunohistochemistry {#cas13526-sec-0010}
-------------------------

We used a tissue microarray that was incubated overnight at 4°C with anti‐PMM2 antibodies (1:100 dilution, SAB2702078; Sigma‐Aldrich). The sliced slides were treated with biotinylated goat antibodies (Histofine SAB‐PO kit; Nichirei, Tokyo, Japan). The procedures were described earlier.[20](#cas13526-bib-0020){ref-type="ref"}, [21](#cas13526-bib-0021){ref-type="ref"}, [22](#cas13526-bib-0022){ref-type="ref"}, [23](#cas13526-bib-0023){ref-type="ref"}, [24](#cas13526-bib-0024){ref-type="ref"}, [25](#cas13526-bib-0025){ref-type="ref"}

2.9. Regulation of targets downstream of *PMM2* in RCC {#cas13526-sec-0011}
------------------------------------------------------

We analyzed *PMM2*‐regulated pathways in RCC cells. We analyzed gene expression using si‐*PMM2*‐transfected 786‐O cells. Microarray data were used for expression profiling of si‐*PMM2* transfectants. The microarray data were deposited into the GEO database (accession no. GSE107008).

2.10. The Cancer Genome Atlas database analysis of RCC {#cas13526-sec-0012}
------------------------------------------------------

To assess the clinical significance of miRNAs and their targeted genes, we used the RNA sequencing database in TCGA. The definition of high and low expression divided half of the clinical data population in the order of expression. Gene expression and clinical data were obtained from cBioportal and OncoLnc (data downloaded November 1, 2017).[27](#cas13526-bib-0027){ref-type="ref"}, [28](#cas13526-bib-0028){ref-type="ref"}, [29](#cas13526-bib-0029){ref-type="ref"}

2.11. Statistical analysis {#cas13526-sec-0013}
--------------------------

Relationships between 2 groups and the numerical values obtained by qRT‐PCR were analyzed by Mann‐Whitney *U*‐tests and paired *t* tests. Spearman\'s rank test was used to analyze the correlation between the expression levels of *miR‐451a* and *PMM2*. Relationships among more than 3 variables and numerical values were analyzed with Bonferroni‐adjusted Mann‐Whitney *U*‐tests. Survival analysis was carried out using the Kaplan‐Meier method, log‐rank tests, and multivariable Cox hazard regression analyses with JMP software (version 13; SAS Institute, Cary, NC, USA). Other statistical analyses were carried out using Expert StatView (version 5; SAS Institute).

3. RESULTS {#cas13526-sec-0014}
==========

3.1. Expression levels of *miR‐451a* in RCC clinical specimens and cell lines {#cas13526-sec-0015}
-----------------------------------------------------------------------------

Expression levels of *miR‐451a* were significantly downregulated in RCC tissues compared with those in non‐cancerous tissues (*P* = .0166; Figure [1](#cas13526-fig-0001){ref-type="fig"}A). Furthermore, expression levels of *miR‐451a* in 786‐O and A498 cells were markedly downregulated (Figure [1](#cas13526-fig-0001){ref-type="fig"}A). In the human genome, *miR‐451a* has formed a miRNA cluster with other miRNAs (*miR‐144‐5p*,*miR‐144‐3p*,*miR‐451b*, and *miR‐4732*) on human chromosome 17q11.2 region (Figure [S1](#cas13526-sup-0001){ref-type="supplementary-material"}). We also checked expression of these miRNAs in RCC clinical specimens. Expression levels of *miR‐144‐5p* and *miR‐144‐3p* were significantly downregulated in RCC tissues. On the contrary, it was revealed that the expression levels of *miR‐451b* and *miR‐4732* were extremely low in normal kidney and RCC tissues (Figure [S1](#cas13526-sup-0001){ref-type="supplementary-material"}).

![Antitumor functions of *miR‐451a* in renal cell carcinoma. A, Expression levels of *miR‐451a* in renal cell carcinoma clinical specimens and cell lines. *RNU48* was used as an internal control. B, Kaplan‐Meier survival curves, as determined using data from The Cancer Genome Atlas database. C, Cell proliferation was determined by XTT assays 72 hours after transfection with *miR‐451a*. D, Cell migration activity. E, Cell invasion activity was determined using Matrigel assays. \**P* \< .0001](CAS-109-1239-g001){#cas13526-fig-0001}

To investigate the molecular mechanisms of silencing of *miR‐451a* in RCC cells, 786‐O cells were treated with the demethylating agent 5‐aza‐2′‐deoxycytidine. Expression of *miR‐451a* was not dramatically elevated by 5‐aza‐2′‐deoxycytidine treatment (Figure [S1](#cas13526-sup-0001){ref-type="supplementary-material"}).

A large cohort analysis (n = 506) using data from TCGA database showed that low expression of *miR‐451a* was associated with poor survival of patients with RCC (*P* = .00305; Figure [1](#cas13526-fig-0001){ref-type="fig"}B).

3.2. Effects of ectopic expression of *miR‐451a* in RCC cell lines {#cas13526-sec-0016}
------------------------------------------------------------------

To investigate the antitumor functions of *miR‐451a* in RCC cells, we applied to gain‐of‐function analyses in this study. Ectopic expression of *miR‐451a* in RCC cell lines (786‐O and A498) did not affect cell proliferation (Figure [1](#cas13526-fig-0001){ref-type="fig"}C). Cell migration and invasion activities were significantly inhibited in *miR‐451a* transfectant cells compared with those in mock or miRNA‐control transfectant cells (Figure [1](#cas13526-fig-0001){ref-type="fig"}D,E).

3.3. Screening of candidate targets by *miR‐451a* regulation in RCC cells {#cas13526-sec-0017}
-------------------------------------------------------------------------

We undertook in silico and gene expression analyses to identify genes targeted by *miR‐451a*. The strategy for selection of *miR‐451a* target genes is shown in Figure [2](#cas13526-fig-0002){ref-type="fig"}. Using the TargetScanHuman 7.0 database, we identified 541 genes that had putative target sites for *miR‐451a* in their 3′‐UTRs. Among these genes, we identified 64 that showed increased expression levels in RCC tissues (fold‐change \>1.5) using the database (GEO database accession number: GSE36895).

![Flow chart illustrating the analytic strategy for *miR‐451a* targets in renal cell carcinoma cells. A total of 541 genes were putative targets of *miR‐451a* in the TargetScan database analysis (release 7.0). We selected 16 genes as putative targets of *miR‐451a* in renal cell carcinoma cells. GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas](CAS-109-1239-g002){#cas13526-fig-0002}

Next, we identified 16 genes that were downregulated after transfection of 786‐O and A498 cells with *miR‐451a* (average log~2~ ratio \< −1.0; Table [2](#cas13526-tbl-0002){ref-type="table-wrap"}). Next, using the OncoLnc database, we investigated whether the expression levels of the 16 candidate genes affected the prognosis of RCC patients. Kaplan‐Meier survival curves revealed that high expression levels of 9 of the genes were associated with poor prognosis in patients with RCC (Figure [3](#cas13526-fig-0003){ref-type="fig"}). Finally, we focused on *PMM2* because it showed the most evident difference in OncoLnc prognostic analysis (*P* = .000000218; Table [2](#cas13526-tbl-0002){ref-type="table-wrap"}, Figure [3](#cas13526-fig-0003){ref-type="fig"}) and there are few reports on cancer studies.

###### 

Candidate target genes regulated by *miR‐451a* in renal cell carcinoma cells

  Gene symbol   Gene name                                                Conserved sites count   Poorly conserved sites count   GEO expression data fold‐change (tumor/normal)   A498 *miR‐451a* transfection (Log~2~ ratio)   786‐O *miR‐451a* transfection (Log~2~ ratio)   Average A498/786‐O *miR‐451a* transfection (Log~2~ ratio)   Cytoband       TCGA data OS (*P*‐value)
  ------------- -------------------------------------------------------- ----------------------- ------------------------------ ------------------------------------------------ --------------------------------------------- ---------------------------------------------- ----------------------------------------------------------- -------------- --------------------------
  *PMM2*        Phosphomannomutase 2                                     1                       0                              1.580                                            −1.617                                        −1.020                                         −1.319                                                      hs\|16p13.2    .000000218
  *CRELD2*      Cysteine‐rich with EGF‐like domains 2                    0                       1                              1.656                                            −1.724                                        −2.256                                         −1.990                                                      hs\|22q13.33   .000000831
  *CLEC2D*      C‐type lectin domain family 2, member D                  0                       1                              2.557                                            −1.014                                        −1.455                                         −1.235                                                      hs\|12p13.31   .00009140
  *SPC25*       SPC25, NDC80 kinetochore complex component               0                       1                              3.213                                            −2.497                                        −2.321                                         −2.409                                                      hs\|2q31.1     .00009800
  *BST2*        Bone marrow stromal cell antigen 2                       0                       1                              2.061                                            −0.668                                        −1.723                                         −1.196                                                      hs\|19p13.11   .00015300
  *EVL*         Enah/Vasp‐like                                           0                       1                              1.896                                            −1.197                                        −1.510                                         −1.354                                                      hs\|14q32.2    .00125000
  *TBX15*       T‐box 15                                                 0                       1                              4.118                                            −1.224                                        −1.618                                         −1.421                                                      hs\|1p12       .00193000
  *DPYSL3*      Dihydropyrimidinase‐like 3                               0                       1                              2.326                                            −1.325                                        −1.344                                         −1.335                                                      hs\|5q32       .00389000
  *NAMPT*       Nicotinamide phosphoribosyltransferase                   0                       1                              2.174                                            −2.369                                        −0.534                                         −1.452                                                      hs\|7q22.3     .01380000
  *MEGF6*       Multiple EGF‐like‐domains 6                              0                       1                              2.112                                            −0.917                                        −1.811                                         −1.364                                                      hs\|1p36.32    .15100000
  *CRIP2*       Cysteine‐rich protein 2                                  0                       1                              1.590                                            −1.899                                        −1.593                                         −1.746                                                      hs\|14q32.33   .18800000
  *CAV1*        Caveolin 1, caveolae protein, 22kda                      0                       1                              6.729                                            −1.196                                        −2.144                                         −1.670                                                      hs\|7q31.2     .20100000
  *PSMB8*       Proteasome (prosome, macropain) subunit, beta type, 8    1                       0                              2.682                                            −1.502                                        −1.906                                         −1.704                                                      hs\|6p21.32    .25500000
  *CDH11*       Cadherin 11, type 2, OB‐cadherin (osteoblast)            0                       1                              1.847                                            −0.791                                        −1.788                                         −1.290                                                      hs\|16q21      .42600000
  *EGLN3*       Egl‐9 family hypoxia‐inducible factor 3                  0                       1                              13.668                                           −0.740                                        −1.940                                         −1.340                                                      hs\|14q13.1    .68800000
  *SLC39A14*    Solute carrier family 39 (zinc transporter), member 14   0                       1                              2.057                                            −1.391                                        −1.386                                         −1.389                                                      hs\|8p21.3     .83600000

GEO, Gene Expression Omnibus; OS, overall survival; TCGA, The Cancer Genome Atlas.
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![The Cancer Genome Atlas database analysis of putative targets of *miR‐451a* in renal cell carcinoma. Kaplan‐Meier plots of overall survival with log‐rank tests for 16 genes with high and low expression from The Cancer Genome Atlas database](CAS-109-1239-g003){#cas13526-fig-0003}

3.4. *PMM2* directly regulated by *miR‐451a* in RCC cells {#cas13526-sec-0018}
---------------------------------------------------------

Expression levels of *PMM2*/PMM2 were reduced by *miR‐451a* transfection at mRNA and protein levels (Figure [4](#cas13526-fig-0004){ref-type="fig"}A,B).

![Regulation of *PMM2* expression by *miR‐451a* in renal cell carcinoma cells. A, Expression levels of *PMM2* mRNA 48 hours after transfection of 10 nmol/L *miR‐451a* into cell lines. *GUSB* was used as an internal control. \**P* \< .0001. B, Protein expression of phosphomannomutase 2 (PMM2) 72 hours after transfection with *miR‐451a*. GAPDH was used as a loading control. C, *miR‐451a* binding sites in the 3′‐UTR of *PMM2* mRNA. D, Dual luciferase reporter assays using vectors encoding putative *miR‐451a* target sites (positions 1127‐1133) in the *PMM2* 3′‐UTR for both wild‐type and deleted regions. Normalized data were calculated as the ratio of *Renilla*/firefly luciferase activities. \**P *\< .005](CAS-109-1239-g004){#cas13526-fig-0004}

Furthermore, we carried out luciferase reporter assays to elucidate whether *PMM2* mRNA had a functional target site for *miR‐451a*. The TargetScan database predicted that *miR‐451a* was bound at position 1127‐1133 in the 3′‐UTR of *PMM2* (Figure [4](#cas13526-fig-0004){ref-type="fig"}C). We used vectors encoding a partial wild‐type sequence of the 3′‐UTR of *PMM2* mRNA, including the predicted *miR‐451a* target site, or a vector lacking the *miR‐451a* target site. Luminescence intensity was significantly reduced by co‐transfection with *miR‐451a* and the vector carrying the wild‐type 3′‐UTR of *PMM2*. In contrast, luminescence intensity was not reduced when the target site of *miR‐451a* was deleted from the vectors (Figure [4](#cas13526-fig-0004){ref-type="fig"}D).

3.5. Effects of *PMM2* knockdown in RCC cell lines {#cas13526-sec-0019}
--------------------------------------------------

To investigate the functional significance of *PMM2*, we carried out loss‐of‐function studies using transfection of si‐*PMM2* into 786‐O and A498 cells. First, we evaluated the knockdown efficiency of si‐*PMM2* transfection, using 2 types of si‐*PMM2* (si‐*PMM2*\_1 and si‐*PMM2*\_2). Using qRT‐PCR and Western blot analyses, we confirmed that the expression levels of *PMM2* mRNA and protein were significantly reduced (Figure [5](#cas13526-fig-0005){ref-type="fig"}A,B). Furthermore, functional assays showed that si‐*PMM2* transfection significantly inhibited cell proliferation, migration, and invasion in comparison with mock or siRNA‐control transfected cells (Figure [5](#cas13526-fig-0005){ref-type="fig"}C‐E).

![Effects of *PMM2* silencing in renal cell carcinoma cell lines. A, *PMM2* mRNA expression 48 hours after transfection with 10 nM si*‐PMM2* into renal cell carcinoma cell lines. *GUSB* was used as an internal control. B, Phosphomannomutase 2 (PMM2) protein expression 72 h after transfection with si‐*PMM2*. GAPDH was used as a loading control. C, Cell proliferation was determined with XTT assays 72 hours after transfection with 10 nM si‐*PMM2*\_1 or si‐*PMM2*\_2. D, Cell migration assessed by wound healing assays. E, Cell invasion activity was determined using a Matrigel system. \**P \< *.0001](CAS-109-1239-g005){#cas13526-fig-0005}

3.6. Expression of *PMM2*/PMM2 in RCC clinical specimens and cell lines {#cas13526-sec-0020}
-----------------------------------------------------------------------

We used qRT‐PCR to investigate the mRNA expression levels of *PMM2* in 15 pairs of RCC tissues, adjacent noncancerous tissues and RCC cell lines. Expression of *PMM2* was significantly upregulated in RCC tissues compared with that in normal tissues (*P* = .0026; Figure [6](#cas13526-fig-0006){ref-type="fig"}A) and also markedly upregulated in RCC cell lines. Furthermore, Spearman\'s rank test revealed a negative correlation between the expression levels of *miR‐451a* and *PMM2* (*P* = .0409, *R* = −.38; Figure [6](#cas13526-fig-0006){ref-type="fig"}B).

![Expression of *PMM2* in clinical specimens of renal cell carcinoma. A, Expression levels of *PMM2* in renal cell carcinoma clinical specimens. *GUSB* was used as an internal control. B, A negative correlation between *PMM2* expression and *miR‐451a* (*R* = −.38 and *P* = .0409). Spearman\'s rank test was used to evaluate the correlation. C, Immunostaining showed that phosphomannomutase 2 (PMM2) was strongly expressed in several cancer lesions (magnification, ×100 \[left panels\] and ×400 \[right panels\])](CAS-109-1239-g006){#cas13526-fig-0006}

Moreover, we carried out immunohistochemistry to analyze PMM2 protein expression in an RCC tissue microarray (cat. no. KD806; US Biomax, Rockville, MD, USA). Patient characteristics for samples used in the tissue microarray are as described in <http://www.biomax.us/tissue-arrays/Kidney/KD806>. The PMM2 protein was strongly expressed in several cancer lesions (Figure [6](#cas13526-fig-0006){ref-type="fig"}C).

3.7. Effects of co‐transfection of *PMM2/miR‐451a* in 786‐O cells {#cas13526-sec-0021}
-----------------------------------------------------------------

We undertook *PMM2* rescue studies in 786‐O cells to elucidate whether the molecular pathway of *PMM2*/*miR‐451a* was significant for the progression of RCC. Figure [7](#cas13526-fig-0007){ref-type="fig"}A shows the results of Western blot analysis of PMM2 protein expression. Functional assays showed that the migration and invasive abilities of RCC cells were significantly recovered by *PMM2* and *miR‐451a* transfection compared with cells transfected with *miR‐451a* alone (Figure [7](#cas13526-fig-0007){ref-type="fig"}C,D). These results suggested that *PMM2* had an important role in the aggressiveness of RCC.

![Effects of co‐transfection of *PMM2*/*miR‐451a* in 786‐O renal cell carcinoma cells. A, Phosphomannomutase 2 (PMM2) protein expression was evaluated by Western blot analysis of 786‐O cells 72 hours after reverse transfection with *miR‐451a* and 48 hours after forward transfection with the *PMM2* vector. GAPDH was used as a loading control. B, Cell proliferation was determined using XTT assays 72 hours after reverse transfection with *miR‐451a* and 48 hours after forward transfection with the *PMM2* vector. C, Cell migration activity was assessed by wound healing assays 48 hours after reverse transfection with *miR‐451a* and 24 hours after forward transfection with the *PMM2* vector. D, Cell invasive activity was characterized by invasion assays 48 hours after reverse transfection with *miR‐451a* and 24 h after forward transfection with *PMM2* vector. \**P* \< .0001. VC, Vector Control](CAS-109-1239-g007){#cas13526-fig-0007}

3.8. Downstream genes affected by silencing of *PMM2* in 786‐O cells {#cas13526-sec-0022}
--------------------------------------------------------------------

We carried out genome‐wide gene expression analyses by transfecting si‐*PMM2* into 786‐O cells to elucidate which genes were modulated by *PMM2* knockdown. We focused on genes that were significantly downregulated by transfection of both si‐*PMM2*\_1 and si‐*PMM2*\_2 (average log~2~ \[si‐*PMM2*/mock\] \< −1.0). Genes significantly downregulated by silencing of *PMM2* are listed in Table [3](#cas13526-tbl-0003){ref-type="table-wrap"}. Among these genes, high expression levels of *CD7*,*CCNE2*,*ASB2*,*RCN3*,*HSF1*,*PAQR4*,*CD37*,*SOX11*,*XAF1*, and *DEPDC1* were associated with poor prognosis in RCC patients based on TCGA database (Figure [8](#cas13526-fig-0008){ref-type="fig"}).

###### 

Candidate downstream genes modulated by *PMM2* in renal cell carcinoma cells

  Gene symbol      Gene name                                                   GEO expression data fold‐change (tumor/normal)   Log~2~ (si‐*PMM2*\_1/mock)   Log~2~ (si‐*PMM2*\_2/mock)   Average Log~2~ (si‐*PMM2*/mock)   Cytoband       TCGA data OS (*P*‐value)
  ---------------- ----------------------------------------------------------- ------------------------------------------------ ---------------------------- ---------------------------- --------------------------------- -------------- ---------------------------------------------------
  *GNLY*           Granulysin                                                  5.987                                            −2.465                       −2.548                       −2.506                            hs\|2p11.2     .09360000
  *TTF2*           Transcription termination factor, RNA polymerase II         1.312                                            −3.407                       −1.139                       −2.273                            hs\|1p13.1     .27800000
  *CD7*            CD7 molecule                                                1.981                                            −1.935                       −2.522                       −2.228                            hs\|17q25.3    .00001220
  *CCNE2*          Cyclin E2                                                   2.430                                            −3.101                       −1.251                       −2.176                            hs\|8q22.1     .00664000
  *NLGN1*          Neuroligin 1                                                2.422                                            −1.377                       −2.500                       −1.938                            hs\|3q26.31    .03910000[\*](#cas13526-note-0501){ref-type="fn"}
  *TMEM184B*       Transmembrane protein 184B                                  1.525                                            −1.128                       −2.639                       −1.883                            hs\|22q13.1    .96300000
  *ASB2*           Ankyrin repeat and SOCS box containing 2                    1.804                                            −2.534                       −1.194                       −1.864                            hs\|14q32.12   .01680000
  *ASPH*           Aspartate β‐hydroxylase                                     1.727                                            −1.414                       −2.244                       −1.829                            hs\|8q12.3     .22000000
  *MAML3*          Mastermind‐like 3 (Drosophila)                              1.364                                            −1.644                       −1.923                       −1.784                            hs\|4q31.1     .00010700[\*](#cas13526-note-0501){ref-type="fn"}
  *RCN3*           Reticulocalbin 3, EF‐hand calcium binding domain            1.314                                            −2.325                       −1.103                       −1.714                            hs\|19q13.33   .00000636
  *CAMK1*          Calcium/calmodulin‐dependent protein kinase I               1.324                                            −1.566                       −1.471                       −1.519                            hs\|3p25.3     .54600000
  *P2RX7*          Purinergic receptor P2X, ligand gated ion channel, 7        8.047                                            −1.746                       −1.134                       −1.440                            hs\|12q24.31   .95700000
  *KDM1B*          Lysine (K)‐specific demethylase 1B                          1.342                                            −1.291                       −1.544                       −1.417                            hs\|6p22.3     .00939000[\*](#cas13526-note-0501){ref-type="fn"}
  *OAS3*           2′‐5′‐oligoadenylate synthetase 3, 100kda                   2.919                                            −1.490                       −1.287                       −1.388                            hs\|12q24.13   .97300000
  *HSF1*           Heat shock transcription factor 1                           1.324                                            −1.685                       −1.083                       −1.384                            hs\|8q24.3     .00126000
  *PMM2*           Phosphomannomutase 2                                        1.580                                            −1.304                       −1.376                       −1.340                            hs\|16p13.2    .000000218
  *CDKN2B*         Cyclin‐dependent kinase inhibitor 2B (p15, inhibits CDK4)   3.355                                            −1.237                       −1.434                       −1.335                            hs\|9p21.3     .00542000[\*](#cas13526-note-0501){ref-type="fn"}
  *PAQR4*          Progestin and adipoq receptor family member IV              5.134                                            −1.567                       −1.087                       −1.327                            hs\|16p13.3    .00152000
  *CD37*           CD37 molecule                                               6.272                                            −1.154                       −1.420                       −1.287                            hs\|19q13.33   .01880000
  *SOX11*          SRY (sex determining region Y)‐box 11                       5.969                                            −1.334                       −1.236                       −1.285                            hs\|2p25.2     .04050000
  *XAF1*           XIAP associated factor 1                                    2.349                                            −1.044                       −1.489                       −1.266                            hs\|17p13.1    .00001720
  *DEPDC1*         DEP domain containing 1                                     2.606                                            −1.253                       −1.197                       −1.225                            hs\|1p31.2     .00011100
  *SAMHD1*         SAM domain and HD domain 1                                  2.764                                            −1.225                       −1.163                       −1.194                            hs\|20q11.23   .16600000
  *P2RY1*          Purinergic receptor p2y, g‐protein coupled, 1               1.427                                            −1.167                       −1.142                       −1.155                            hs\|3q25.2     .00051400[\*](#cas13526-note-0501){ref-type="fn"}
  *LOC100422737*   Uncharacterized loc100422737                                1.322                                            −1.093                       −1.199                       −1.146                            hs\|6q21       No data
  *DOCK9*          Dedicator of cytokinesis 9                                  1.614                                            −1.158                       −1.087                       −1.123                            hs\|13q32.3    .00001100[\*](#cas13526-note-0501){ref-type="fn"}
  *SLC39A10*       Solute carrier family 39 (zinc transporter), member 10      1.331                                            −1.074                       −1.137                       −1.105                            hs\|2q32.3     .01820000[\*](#cas13526-note-0501){ref-type="fn"}
  *RNF125*         Ring finger protein 125, e3 ubiquitin protein ligase        1.526                                            −1.060                       −1.060                       −1.060                            hs\|18q12.1    .03820000[\*](#cas13526-note-0501){ref-type="fn"}

GEO, Gene Expression Omnibus; OS, overall survival; TCGA, The Cancer Genome Atlas.

\*, poor prognosis with low expression.

John Wiley & Sons, Ltd

![The Cancer Genome Atlas database analysis of *PMM2*‐mediated downstream genes in renal cell carcinoma. Kaplan‐Meier curves of 10 genes whose high expression levels were associated with poor prognosis in renal cell carcinoma](CAS-109-1239-g008){#cas13526-fig-0008}

3.9. Clinical significance of *PMM2* in RCC pathogenesis using TCGA database {#cas13526-sec-0023}
----------------------------------------------------------------------------

To investigate the clinical significance of *PMM2* in RCC pathogenesis, we asked whether the *PMM2* expression level affected disease‐free survival (DFS) in RCC. We found that high expression levels of *PMM2* were significantly associated with low DFS in RCC patients (*P \< *.0001; Figure [9](#cas13526-fig-0009){ref-type="fig"}A). Furthermore, we analyzed the relationships among *PMM2* expression levels and tumor T stage, lymph node metastasis, disease stage, and histologic grade in RCC. *PMM2* expression levels were significantly higher in the more advanced tumor stages and histologic grades (Figure [9](#cas13526-fig-0009){ref-type="fig"}B‐E).

![Kaplan‐Meier curves for disease‐free survival based on *PMM2* expression in patients with renal cell carcinoma, and expression levels of *PMM2* according to T stage, N stage, tumor stage, and histologic grade. All patients' data were obtained from The Cancer Genome Atlas database. A, Kaplan‐Meier survival curves for disease‐free survival based on *PMM2* expression in patients with renal cell carcinoma. B‐E, Relationships between expression levels of *PMM2* and T stage, N stage, disease stage, and histologic grade. \**P* \< .05, \*\**P* \< .005, \*\*\**P* \< .0001](CAS-109-1239-g009){#cas13526-fig-0009}

Additionally, we undertook univariable and multivariable Cox hazard regression analyses to investigate the clinical significance of *PMM2* expression along with other clinical factors in the overall survival of RCC patients. Multivariate analysis showed that high *PMM2* expression and tumor stage were independent predictive factors for overall survival (hazard ratio = 1.26, *P* = .0487 and hazard ratio = 0.76, *P* = .0353, respectively; Table [4](#cas13526-tbl-0004){ref-type="table-wrap"}). These results suggested that *PMM2* may be closely associated with tumor progression and malignancy in RCC.

###### 

Univariable and multivariable Cox hazard regression models for overall survival in renal cell carcinoma

  Variable                Group               Univariable   Multivariable                               
  ----------------------- ------------------- ------------- --------------- ------- ------ ------------ -------
  *PMM2* expression       High/low            1.35          1.10‐1.68       .0047   1.26   1.002‐1.58   .0487
  Age, years              \<60/≥60            0.78          0.64‐0.97       .0265   0.82   0.66‐1.01    .0703
  Gender                  Male/female         1.13          0.90‐1.41       .279    ‐      ‐            ‐
  Stage                   I+II/III+IV         0.67          0.52‐0.84       .0007   0.76   0.59‐0.98    .0353
  Histologic grade        G1+2/G3+4           0.68          0.55‐0.85       .0006   0.81   0.64‐1.03    .0896
  Lymph node metastasis   Positive/negative   1.25          0.44‐2.74       .648    ‐      ‐            ‐

‐, Not analyzed in multivariate analysis; CI, confidence interval; HR, hazard ratio.

John Wiley & Sons, Ltd

4. DISCUSSION {#cas13526-sec-0024}
=============

The aberrant expression of miRNAs disrupts regulated RNA networks in various type of cancer cells and therefore contributes substantially to the pathogenesis of human cancer.[30](#cas13526-bib-0030){ref-type="ref"} Therefore, understanding miRNA signatures is essential to clarifying their roles in the pathology of human cancer cells. We previously characterized several miRNAs that had significant antitumor functions in RCC cells. For example, *miR‐101* was significantly reduced in RCC tissues and the restoration of *miR‐101* inhibited RCC aggressiveness through targeting the *UHRF1* gene.[9](#cas13526-bib-0009){ref-type="ref"} More recently, we showed that *miR‐10a‐5p* was downregulated in primary and tyrosine‐kinase inhibitor‐treated RCC specimens and directly regulated the *SKA1* gene. *SKA1* was overexpressed and knockdown of *SKA1* inhibited migration and invasion of RCC cells.[22](#cas13526-bib-0022){ref-type="ref"}

Our present data showed that expression of *miR‐451a* was significantly reduced in primary RCC. Furthermore, ectopic expression of *miR‐451a* resulted in inhibition of cancer cell migratory and invasive abilities in RCC, indicating that *miR‐451a* functions as a tumor suppressor in RCC. Previous reports showed that expression of *miR‐451* was downregulated in several types of human cancers. In bladder cancer, *miR‐451* expression was significantly reduced in cancer tissues compared with adjacent tissues and that restoration of *miR‐451* reduced cancer cell migration and invasive abilities.[31](#cas13526-bib-0031){ref-type="ref"}, [32](#cas13526-bib-0032){ref-type="ref"} Furthermore, low expression of *miR‐451* was associated with advanced tumor stage and high pathological grade in bladder cancer.[32](#cas13526-bib-0032){ref-type="ref"} Our previous data showed that *miR‐451a* acted as an antitumor miRNA through targeting *ESDN*/*DCBLD2* in head and neck squamous cell carcinoma.[12](#cas13526-bib-0012){ref-type="ref"}

In this study, we identified 16 putative oncogenic targets by *miR‐451a* regulation in RCC cells. Interestingly, among these targets, expression of 9 genes (*PMM2*,*CRELD2*,*CLEC2D*,*SPC25*,*BST2*,*EVL*,*TBX15*,*DPYSL3*, and *NAMPT*) were significantly associated with poor prognosis of the patients with RCC by TCGA database analyses. These targets might be potential therapeutic targets for RCC and the search for RNA networks controlled by antitumor *miR‐451a* and its targets are important for elucidation of the pathogenesis of RCC. In the present study, we identified *PMM2* as an oncogenic gene in RCC cells. Moreover, overexpressed *PMM2* was involved RCC pathogenesis. *PMM2* codes for an enzyme that converts mannose‐6‐phosphate to mannose‐1‐phosphate and participates in a metabolic pathway in glycan synthesis.[33](#cas13526-bib-0033){ref-type="ref"}, [34](#cas13526-bib-0034){ref-type="ref"}, [35](#cas13526-bib-0035){ref-type="ref"} Protein glycosylation is an important contributor to cancer progression, including cell growth, tumor‐induced immunomodulation, and eventual metastasis.[36](#cas13526-bib-0036){ref-type="ref"} Previous reports indicated that cancer cells, including RCC, are characterized by an aberrant increase in protein N‐glycosylation.[37](#cas13526-bib-0037){ref-type="ref"}, [38](#cas13526-bib-0038){ref-type="ref"} In clear cell RCC, upregulation of protein glycosylation in cancer cells may be useful in diagnosis and determining disease prognosis.[39](#cas13526-bib-0039){ref-type="ref"} Furthermore, N‐glycosylation is involved in cell adhesion and is associated with reduced expression of E‐cadherin, which modulates the metastatic potential of cancer cells.[37](#cas13526-bib-0037){ref-type="ref"}, [40](#cas13526-bib-0040){ref-type="ref"} We hypothesize that this pathway might contribute to cancer pathogenesis such that upregulation of *PMM2* might enhance cancer cell aggressiveness by increased N‐glycosylation. In support of this hypothesis, TCGA database showed that high expression of *PMM2* was associated with poor prognosis even in other types of cancer, for example, bladder cancer, breast cancer, head and neck squamous cell carcinoma, glioma, and melanoma (Figure [S2](#cas13526-sup-0002){ref-type="supplementary-material"}).

Interestingly, a previous report showed that *miR‐451* was controlled by glucose levels and regulated cancer aggressiveness through the AMP‐activated protein kinase pathway and mTOR activation in glioblastoma.[15](#cas13526-bib-0015){ref-type="ref"} Thus, *miR‐451* regulated pathways may be involved in glucose‐related metabolic pathways and regulate cancer aggressiveness. Further research into *miR‐451*/*PMM2‐*modulated pathways in cancer will be necessary. To investigate *PMM2*‐mediated pathways in RCC, we undertook genome‐wide gene expression analyses using *PMM2* knockdown cells. We identified 27 genes that were regulated by *PMM2* in RCC. Among them, the expression of 10 genes was elevated (*CD7*,*CCNE2*,*ASB2*,*RCN3*,*HSF1*,*PAQR4*,*CD37*,*SOX11*,*XAF1*, and *DEPDC1*) and their expression levels were significantly associated with poor prognosis in RCC patients according to TCGA database (*P* \< .05). Elucidation of novel *PMM2*‐mediated pathways may improve our understanding of RCC aggressiveness.

In conclusion, our data revealed that expression of *miR‐451a* was significantly downregulated in clinical RCC cells. Moreover, *miR‐451a* acted as a tumor suppressor through the targeting of *PMM2*. Phosphomannomutase 2 was strongly expressed in RCC cells and its silencing significantly inhibited cancer cell migration and invasive abilities. In clinical analysis, high expression of *PMM2* was significantly associated with shorter DFS and lower survival rates. In short, *PMM2*‐regulated genes are deeply involved in RCC pathogenesis. Elucidation of the pathways mediated by the *miR‐451a*/*PMM2* axis should improve our understanding of oncogenic mechanisms and lead to new treatment strategies in RCC.
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